On September 8, 2019 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that the company will hold a conference call and webcast on Sunday, September 8, 2019, at 7:00 p.m. ET | Monday, September 9, 2019, at 7:00 a.m.Hong Kong time, prior to the open of trading on the Hong Kong Stock Exchange (Press release, BeiGene, SEP 8, 2019, View Sourcenews-releases/news-release-details/beigene-hold-conference-call-and-webcast-september-8-2019-700-pm" target="_blank" title="View Sourcenews-releases/news-release-details/beigene-hold-conference-call-and-webcast-september-8-2019-700-pm" rel="nofollow">View Source [SID1234539358]). On the call, Company management will provide information related to a recent short seller report commenting on the Company’s operations .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast Information
Investors and analysts are invited to join the conference call using the following dial-in information:
U.S. Toll-Free: (844) 461-9930
Hong Kong: 5819-4851
China: 400-682-8609
Conference ID: 7797578

A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available two hours after the event for 90 days.